Astrion Inc. was founded in August 2022 by two co-founders Dr. Jae Yong Park and In Duk Jung. The company currently 14 employees. We are developing drugs for three indications: glioblastoma, head and neck cancer and Parkinson’s disease. For glioblastoma drug candidates which is being developed in priority, we have discovered 8 small molecules with our own screening platform and AON-MG23 is leading compound that aggressively studied in vitro and in vivo efficacy forwarding the non-clinical approach. Once data are obtained from those studies, one lead compound will be chosen to conduct GLP toxicology study which is planned for end of this year. After that our plan is to enter clinical trial at 2025. For Parkinson’s disease, we are now on the discovery phase. We have discovered 10 molecules with our own screening system and working on the chemical design level to improve the solubility and invitro efficacy. We are planning to start GLP toxicology study with in third quarter of 2024.